outlined.' Dr Haque, in reference to our work, questions the 'justification of giving weekly painful and costly injections '. At the time of the conception and early stages of our study, intravenous immunoglobulin preparations had not received full product licencing in this country. May I remind Dr Haque that our study was approved by the hospital ethical committee and that we would not have given these infants intramuscular injections except as a logical extension of our previous work2 and in reasonable expectation of their being of benefit to the child. The cost of prophylactic immunoglobulin treatment, if successful, is more than offset by the saving in expensive antibiotic use.
I absolutely refute Dr Haque's suggestion of possible nursing bias. The substantiation of a doctor's academic hypothesis weighs little with our intensive care nurses compared with the continued well being of their patients. Moreover, in a busy regional unit with much active research in progress, every nurse was not necessarily always aware of which baby was, or was not, receiving immunoglobulin treatment.
The preparation used contained 250 mg in 1-7 ml and volumes injected were therefore small. As We studied 64 patients with cystic fibrosis measuring HbA, by ion exchange column chromatography and spectrophotometry (Biorad haemoglobin Al by column test) expressed as a percentage of the total haemoglobin. Our laboratory reference range is 5*3-8-8% representing 2 SD limits of the mean in normal paediatric departments. Forty three patients with cystic fibrosis had a mean (SD) HbA, concentration of 7-8 (09)%, range 5-9-8 8. This was not statistically different from the mean HbAj concentration of 7*4 (094)% of 21 normal children admitted for routine operations. All the patients with cystic fibrosis were on long term antibiotic prophylaxis mainly with 0i lactam antibiotics. HbA1 concentrations were obtained on each of the 43 patients with cystic fibrosis on one to four occasions. There was no statistical difference between the mean HbA1 concentration of 7-6 (0-9)% (n=43) of the patients treated with flucloxacillin for at least a two to three month period before estimation and the mean HbA, concentration of 7-7 (08)% (n=24) for patients on both flucloxacillin and ampicillin. These did not differ from the HbA, concentrations of the control population. We found evidence of impaired i cell function in patients with raised HbA, concentrations by measurement of C pe?tide concentrations during oral glucose tolerance test.
Thus there was no evidence from our study that 0i lactam antibodies produce falsely raised HbAI concentrations using the Biorad method. Although Fluckiger reports a potential problem, the evidence that it should deter the measurement of HbAt in patients with cystic fibrosis other than by specific techniques is lacking.
with cancer. 
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